© PR Newswire
29.01.2026
VEEV
LISTED
NYSE
Veeva kündigt eSource-Anwendung für Forschungsstandorte an, um Papier zu eliminieren und den Datenfluss in klinischen Studien zu optimieren
News Preview
Befreit Websites von doppelten Dateneingaben und verbindet EHR und EDC für qualitativ hochwertigere Studiendaten und schnellere ErgebnissePLEASANTON, Kalifornien, 29. Januar 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) hat heute Veeva eSource vorgestellt, eine neue Veeva-SiteVault-Anwendung, die darauf ausgelegt ist, manuelle Prozesse bei klini...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
AB
LISTED
EURONEXT
AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer
News Preview
PRESS RELEASE...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
29.01.2026
MRNA
LISTED
NASDAQ
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)
News Preview
Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition to commercial and sales milestones and tiered royalties on net sales CAMBRIDGE, MA / ACCESS Newswire / January 29, 2026 / Moderna, Inc. (NASDAQ:MRNA) toda...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© ACCESS Newswire
29.01.2026
PBSV
LISTED
OTC
Pharma-Bio Serv Announces Full Year Results and Special Dividend
News Preview
DORADO, PR / ACCESS Newswire / January 29, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and a...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© PR Newswire
29.01.2026
RXRX
LISTED
NASDAQ
AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift
News Preview
Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, Jan. 29, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The global AI medical imaging market exploded to a staggering $2.57 trillion in 2026 as the entire healthcare ecosystem ditched trial-and-error medicine for AI-native diagnostic precision and autonomous operations[1]. T...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
RXRX
LISTED
NASDAQ
AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift
News Preview
Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, Jan. 29, 2026 /CNW/ -- Equity-Insider.com News Commentary – The global AI medical imaging market exploded to a staggering $2.57 trillion in 2026 as the entire healthcare ecosystem ditched trial-and-error medicine for AI-native diagnostic precision and autonomous operations[1]. This mas...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
ALK B
LISTED
CPH
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children
News Preview
Inside Information...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
389650
LISTED
KOE
NEXTBIOMEDICAL Secures Health Canada Approval for Nexsphere-F™ in Musculoskeletal Pain Embolization
News Preview
SEOUL, South Korea, Jan. 29, 2026 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval from Health Canada....
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2026
ANEB
LISTED
NASDAQ
Anebulo Pharmaceuticals Announces Final Results of Tender Offer
News Preview
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced the final results of its voluntary self-tender offer to purchase 300,000 shares of its common stock, par value $0.001 per share...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2026
HIMS
LISTED
NYSE
Hims & Hers Returns to the Big Game with a Message to All Americans: The Era of Health as a Luxury is Over
News Preview
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, announced that it’s heading back to the Big Game this year. On February 8th, Hims & Hers will follow up its hit “Sick of the System” ad, debuting a new national spot “Rich People Live Longer” with a simple message: the era of health as a lux...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC
LEI: 5493003YBCY4W1IMJU04
NET ASSET VALUE
The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
CNC
LISTED
NYSE
Meridian Health Plan of Illinois and Centene Foundation Award $2.2 Million Grant to Safer Foundation for Purchase and Renovation of Affordable Housing Building in Chicago
News Preview
Safer Foundation to Offer 23 Affordable Rental Units for Underserved Individuals in the Austin NeighborhoodCHICAGO, Jan. 29, 2026 /PRNewswire/ -- Meridian Health Plan of Illinois, Inc. (Meridian) and the Centene Foundation today announced a $2.2 million grant to Safer Foundation (Safer), one of the nation's largest nonprofits providing reentry ass...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
29.01.2026
HCA
LISTED
NYSE
HCA Healthcare Hospitals Named on America’s 50 Best Hospitals List for 2026 by Healthgrades
News Preview
HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced that three of its hospitals were named among America’s 50 Best Hospitals and 15 of its hospitals were named among America’s 100 Best Hospitals by Healthgrades. These are part of the 44 HCA Healthcare hospitals recognized on the Healthgrades America’s...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2026
BIO
LISTED
NYSE
Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
News Preview
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2025 on Thursday, February 12, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2026
BAYN
LISTED
XETR
Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign
News Preview
Today Bayer announced it has teamed up with former professional quarterback, Tony Romo, on ‘Highlights REAL,’ a campaign celebrating everyday moments. Tony is joined by his father Ramiro, who has personally faced prostate cancer, to provide play-by-play commentary, not on football, but of advanced prostate cancer patients and their caregivers, fos...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
TRUL
LISTED
CSE
Trulieve Announces Closing of US$60 Million Private Placement of 10.5% Senior Secured Notes
News Preview
TALLAHASSEE, Fla., Jan. 29, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced that, further to its December 17, 2025 news release, it has closed a second tranche of its previously announced private placement of 10.5% Seni...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
TRUL
LISTED
CSE
Trulieve Announces Closing of US$60 Million Private Placement of 10.5% Senior Secured Notes
News Preview
TALLAHASSEE, Fla., Jan. 29, 2026 /CNW/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced that, further to its December 17, 2025 news release, it has closed a second tranche of its previously announced private placement of 10.5% Senior Secu...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
HCTI
LISTED
NASDAQ
Healthcare Triangle Inc. Partners with Better.care to Expand Health Data Platform Services Across EMEA's Leading Healthcare Systems
News Preview
Partnership positions Healthcare Triangle as preferred service provider across high-growth healthcare markets in Europe, Southeast Asia, Middle East, and AfricaPLEASANTON, Calif., Jan. 29, 2026 /CNW/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions including managed services, cloud...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
HCTI
LISTED
NASDAQ
Healthcare Triangle Inc. Partners with Better.care to Expand Health Data Platform Services Across EMEA's Leading Healthcare Systems
News Preview
Partnership positions Healthcare Triangle as preferred service provider across high-growth healthcare markets in Europe, Southeast Asia, Middle East, and AfricaPLEASANTON, Calif., Jan. 29, 2026 /PRNewswire/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions including managed services...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
UNCY
LISTED
NASDAQ
UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
News Preview
LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (N...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
PLCN
LISTED
CSE
Cannibble Food-Tech Ltd. CEO Issues Letter to Shareholders
News Preview
ROSH HAAYIN, Israel, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Cannibble Food-Tech Ltd. (CSE: PLCN) (“Cannibble” or the “Company”) today announced that Yoav Bar-Joseph, founder and chief executive officer, has issued the following letter to shareholders....
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
ABBV
LISTED
EURONEXT
AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships
News Preview
~3 out of 4 respondents said migraine attacks have stood in the way of romantic relationships, according to new Harris Poll surveyWife, mother, country music star, and entrepreneur Jessie James Decker shares her personal experience living with migraineLove in Mind encourages candid conversations about migraine with healthcare providers to develop...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
VEEV
LISTED
NYSE
Veeva Announces eSource Application for Research Sites to Eliminate Paper and Streamline Clinical Trial Data Flow
News Preview
Frees sites from duplicate data entry and connects EHR and EDC for higher quality trial data, fasterPLEASANTON, Calif., Jan. 29, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva eSource, a new Veeva SiteVault application designed to significantly reduce manual clinical trial processes and increase data quality. Veeva eSource w...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
302440
LISTED
KOE
SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family
News Preview
Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus FamilyNext-generation vaccine leveraging SKYCovione's recombinant protein-based platform and nanoparticle technologySK bioscience will continue to strengthen a Mid- to Long-Term global vaccine strategy centered on universal vaccines for future pandemic prepa...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
VEEV
LISTED
NYSE
Veeva Announces eSource Application for Research Sites to Eliminate Paper and Streamline Clinical Trial Data Flow
News Preview
Frees sites from duplicate data entry and connects EHR and EDC for higher quality trial data, fasterPLEASANTON, Calif., Jan. 29, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva eSource, a new Veeva SiteVault application designed to significantly reduce manual clinical trial processes and increase data quality. Veeva eSource w...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
2228
LISTED
HKSE
XtalPi Convenes Global Experts to Shape the Future of Molecular Glue Drug Discovery: From Serendipity to Precision
News Preview
Global thought leaders presented cutting-edge research at the 2026 International Symposium on Molecular Glue Drug Discovery.XtalPi unveils the AI-driven XGlue™ platform to enable rapid, closed-loop molecular glue drug discovery.Cross-sector discussions emphasized the need for bridging gaps between academic research, industrial development, and cli...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
DRTS
LISTED
NASDAQ
Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
News Preview
- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in cancers of internal organs including the pancreas and brain -...
Themefolio
Profiler
Peergroup
© Newsfile
29.01.2026
TELO
LISTED
TSX
Telo Genomics Announces Appointment of John Price as Chief Financial Officer
News Preview
Toronto, Ontario--(Newsfile Corp. - January 29, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that John Price has been appointed as Chief Financial Office...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2026
IQV
LISTED
NYSE
IQVIA and Boehringer Ingelheim announce strategic long-term global commercial data foundation transformation collaboration
News Preview
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced a strategic long-term collaboration with Boehringer Ingelheim. Boehringer Ingelheim has selected IQVIA’s Data-as-a-Service (DaaS+) technology offering as the acce...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2026
ENVB
LISTED
NASDAQ
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option
News Preview
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that its subsidiary, Akos Biosciences, has licensed to TOTEC Pharma, Inc. (“TOTEC”) its US Trademark portfolio for RCANN™ and...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2026
ALNY
LISTED
NASDAQ
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2025 on Thursday, February 12, 2026, before the U.S. financial markets open.
Management will provide an update on the Company and discuss fourth quarter and...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
AIAI
LISTED
CSE
NetraMark Strengthens Board Of Directors
News Preview
TORONTO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced that Lawrence Guy is joining the Company’s Bo...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
CERT
LISTED
NASDAQ
Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025
News Preview
RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2025 before market open on Thursday, February 26th, 2026. Company management will host a conference call to discuss financia...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
CRMD
LISTED
NASDAQ
CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026
News Preview
BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will host an in-person and virtual analyst day in New York on Tuesday, February 10, 2026 wi...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2026
OGN
LISTED
NYSE
Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
News Preview
Organon (NYSE: OGN), a global healthcare company with a primary focus on women’s health, will release its fourth quarter and full year 2025 financial results on February 12, 2026, prior to the company’s webcast and conference call scheduled for 8:30 a.m. ET.
IPR&D and Milestones
Organon does not currently expect to record any milestone exp...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2026
SMMT
LISTED
NASDAQ
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the U.S. Food & Drug Administration (FDA) has accepted for filing Summit's Biologics License Application (BLA) seeking approval for ivonescimab in combination with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated locally...
Themefolio
Profiler
Peergroup
© EQS Newswire
29.01.2026
HPHA
LISTED
XETR
Heidelberg Pharma erhält Meilensteinzahlung des Partners Takeda
News Preview
PRESSEMITTEILUNG
Heidelberg Pharma erhält Meilensteinzahlung des Partners Takeda
Ladenburg, 29. Januar 2026 – Die Heidelberg Pharma AG (FWB: HPHA), ein Entwickler innovativer Antikörper-Wirkstoff-Konjugate (ADCs), gab heute bekannt, dass sie vom Partner Takeda im Rahmen der Lizenzvereinbarung eine Meilensteinzahlung erhalten hat. Diese basiert a......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.01.2026
HPHA
LISTED
XETR
Heidelberg Pharma Received Development Milestone Payment from Partner Takeda
News Preview
PRESS RELEASE
Heidelberg Pharma Received Development Milestone Payment from Partner Takeda
Ladenburg, Germany, 29 January 2026 - Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it has received a milestone payment under the terms of its license agreemen......
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
FTRE
LISTED
NASDAQ
Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call
News Preview
DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026. Fortrea will host a conference call at 8:00 am ET that d...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
RVMD
LISTED
NASDAQ
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
News Preview
REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient was dosed in its first-in-human clinical trial evaluating RMC-5127, a RAS(ON) G12V-selective inhibitor....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
IMM
LISTED
ASX
Immutep Quarterly Activities Report Q2 FY26
News Preview
Media Release...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
IXHL
LISTED
NASDAQ
Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board
News Preview
Incannex appoints three new experts to its Clinical Advisory Board, strengthening guidance as PSX-001 advances in clinical development....
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2026
UNH
LISTED
NYSE
UnitedHealthcare’s AI-powered Capability Helps Identify and Distribute More Cash Payments for Members
News Preview
UnitedHealthcare today released new data showing how Benefit Assist® is helping consumers get cash back from their health plan. This AI-enabled program is designed to help automatically identify when members may qualify for supplemental health payments and has delivered nearly four times more cash benefits to eligible members compared to other pla...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2026
DFTX
LISTED
NASDAQ
Definium Therapeutics Appoints Roger Adsett to Board of Directors
News Preview
Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately.
“We are thrilled to welcome Roger to our Board of Directors,” said Rob Barrow, Chief Executive Officer of Definium Therapeutics. “Roger is a respected and proven leader with deep exp...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
BDX
LISTED
NYSE
BD and Envetec Demonstrate Closed-Loop Recycling Solution for Laboratory Plastics in Health Care
News Preview
Study Opens Door to Sustainable Path for Polystyrene Petri Dishes, PET Tubes, Medical Tubing, and Polypropylene Syringes Across Healthcare Supply ChainsFRANKLIN LAKES, N.J. and BIRDHILL, Colo. and TIPPERARY, Ireland, Jan. 29, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Envet...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
VANI
LISTED
NASDAQ
Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026
News Preview
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology ...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
GLAS.A.U
LISTED
NEO
Glass House Brands Announces Appointment of Alison Payne, Heineken USA Chief Marketing Officer, to its Board of Directors
News Preview
Ms. Payne brings decades of international marketing experience from Heineken, PepsiCo, Kellog and Diageo, where she specializes in branding regulated consumer products Ms. Payne brings decades of international marketing experience from Heineken, PepsiCo, Kellog and Diageo, where she specializes in branding regulated consumer products...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
IFRX
LISTED
NASDAQ
InflaRx Announces Participation in February Investor Conferences
News Preview
JENA, Germany, Jan. 29, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in several investor conferences in February 2026. Details are as follows:...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
UNCY
LISTED
NASDAQ
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
News Preview
LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (N...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
1672
LISTED
HKSE
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
News Preview
- Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study- The exceptional efficacy of denifanstat (ASC40) observed in the Company's previously reported placebo-controlled Phase III trial coupled with a favorable safety profile in two Phase III tr...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
WST
LISTED
NYSE
West to Host Fourth-Quarter and Full-Year 2025 Conference Call
News Preview
EXTON, Pa., Jan. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 12, 2026, and will follow with a conference call...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
1672
LISTED
HKSE
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
News Preview
- Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study- The exceptional efficacy of denifanstat (ASC40) observed in the Company's previously reported placebo-controlled Phase III trial coupled with a favorable safety profile in two Phase III tr...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
CBUS
LISTED
NASDAQ
Cibus, Inc. Announces Pricing of $20.0 Million Public Offering of Class A Common Stock
News Preview
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced the pricing of an underwritten public offering of 13,333,333 shares of its Class A Common Stock, par value $0.0001 per share (“Clas...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
GUTS
LISTED
NASDAQ
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation
News Preview
Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
News Preview
Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
SKYE
LISTED
NASDAQ
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
News Preview
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today presented a poster titled "Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2026
TMO
LISTED
NYSE
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results
News Preview
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2025.
Fourth Quarter and Full Year 2025 Highlights
Fourth quarter revenue grew 7% to $12.21 billion.
Fourth quarter GAAP diluted earnings per share (EPS) grew 9% to $5....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
SAILIFE
LISTED
BSE
マブテックとサイ・ライフ・サイエンシズ、サイのボストン事業所でイーラ・プラットフォームを用いて免疫学研究を推進するための戦略的提携を発表
News Preview
ボストンおよびストックホルム発, Jan. 29, 2026 (GLOBE NEWSWIRE) -- 先進的イムノアッセイに特化した世界的なライフサイエンスツール企業であるマブテック (Mabtech) と、主要な統合型医薬品研究開発製造受託機関 (CRDMO) であるサイ・ライフ・サイエンシズ (Sai Life Sciences) は本日、ボストンにあるサイのラボラトリーが、マブテックのイーラ (EYRA™) プラットフォームの米国実行・デモンストレーション拠点となり、共同マーケティングを行う戦略的提携を発表した。本提携により、マブテックとサイは、サイのボストン創薬拠点に設置されたイーラ・プラットフォームを活用し、高感度マルチプレックスサイトカインや表現型解析ワークフローを含む先進的...
Themefolio
Profiler
Peergroup
© EQS Newswire
29.01.2026
HIGH
LISTED
XETRA
Montega AG: CANTOURAGE GROUP SE | Rating: Kaufen
News Preview
Original-Research: CANTOURAGE GROUP SE - von Montega AG
29.01.2026 / 10:14 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum......
Themefolio
Profiler
Peergroup
© ACCESS Newswire
29.01.2026
VSEE
LISTED
NASDAQ
Rural Hospitals Don't Need More Beds - They Need Smarter Capacity, Like Mobile ICUs
News Preview
SAN JOSE, CALIFORNIA / ACCESS Newswire / January 29, 2026 / VSee Health (Nasdaq:VSEE), a leader in innovative telehealth technology, today announced it will be hosting a live webinar, "The On‑Demand ICU: Sustainable Rural Healthcare," February 4, 2026, 11:00 AM PT / 2:00 PM ETRural hospitals are under pressure like never before. Rising pa...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
